What is HC Wainwright’s Forecast for CGTX Q1 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Cognition Therapeutics in a note issued to investors on Friday, March 27th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS and Q4 2027 earnings at ($0.05) EPS.

Other equities research analysts also recently issued research reports about the stock. raised shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of Cognition Therapeutics in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Friday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Cognition Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $3.33.

Cognition Therapeutics Stock Performance

Shares of CGTX opened at $0.59 on Monday. Cognition Therapeutics has a twelve month low of $0.22 and a twelve month high of $3.83. The firm’s 50 day moving average price is $1.11 and its two-hundred day moving average price is $1.41. The firm has a market cap of $53.13 million, a P/E ratio of -1.80 and a beta of 1.25.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.04.

Hedge Funds Weigh In On Cognition Therapeutics

Several hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. raised its holdings in shares of Cognition Therapeutics by 34.7% in the third quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock valued at $40,000 after purchasing an additional 7,641 shares during the last quarter. Bryn Mawr Trust Advisors LLC boosted its holdings in Cognition Therapeutics by 69.1% during the third quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock worth $53,000 after purchasing an additional 16,129 shares during the last quarter. Jones Financial Companies Lllp bought a new position in Cognition Therapeutics in the third quarter valued at $25,000. Essex Financial Services Inc. bought a new position in Cognition Therapeutics in the fourth quarter valued at $27,000. Finally, Gamco Investors INC. ET AL acquired a new stake in Cognition Therapeutics in the 3rd quarter valued at $27,000. 43.35% of the stock is owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.